Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

03 July 2024 : Clinical Research  

Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-Cell Lymphoma

Jie Wang1ABCDEFG*, Ming Yang2CD, Sheng Chen2CEF, Hongbo Zhu1AB, Zhirong Zhang1CD

DOI: 10.12659/MSM.943551

Med Sci Monit 2024; 30:e943551

Table 2 Correlation between CST1 and the clinicopathological factors.

CharactersCST1P*Effect size
LowHigh
Gender
 Male40140.6880.044
 Female219
Age
 ≤6046160.5890.059
 >60157
Tumor diameter (cm)
 ≤52660.1640.152
 >53517
Macroscopic type
 Ulcerative39130.184
 Polypoid760.242
 Others154
Lesion number
 Single50180.7000.042
 Multiple115
Site
 Stomach35120.6680.047
 Intestine2611
Chemotherapy
 No3190.4770.104
 Yes3014
Serum LDH
 Normal43110.0530.211
 High1812
PS
 <255180.1490.157
 2–465
Luanguo stage
 I–II149160.2930.115
 II2–IV127
IPI
 <359180.0070.298
 3–525
* chi-square test.
LDH – lactate dehydrogenase; PS – performence status; IPI – International Prognostic Index; CST1 – Cystatin SN.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750